IMC Logo.jpg
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
June 12, 2019 07:00 ET | Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
IMC Logo.jpg
Immuron Signs Shigella Vaccine Development Agreement with US Army
June 23, 2016 09:07 ET | Immuron Limited
MELBOURNE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has...